Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

Conditions: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Crizotinib; Procedure: Radiologic Examination Sponsors: National Cancer Institute (NCI) Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials